OBJECTIVE: Measurement of plasma 25-hydroxyvitamin D (25OHD) level is often used to evaluate a patient's vitamin D status. The purpose of this study was to investigate the variability in individual plasma 25OHD- and vitamin D-bindingprotein- (Gc) levels over a 5-year period in postmenopausal women with and without hormone replacement therapy (HRT). MATERIAL AND METHODS: A total of 187 women were followed-up for 5 years. At baseline, 89 women were allocated to treatment with HRT, given orally. Measurements were performed at baseline and after 1, 2 and 5 years of follow-up. RESULTS: At baseline, 25OHD levels were positively associated with sunbathing and use of vitamin D supplements, and inversely associated with smoking. HRT therapy increased plasma levels of Gc (+8 %) but did not affect 25OHD levels or the free 25OHD index (molar ratio of 25OHD- to Gc levels). Among those classified in the lowest 25OHD tertile at baseline, 40 % remained in the lowest tertile during all subsequent measurement time-points. Similarly, 32 % of those classified in the highest baseline tertile remained in the highest tertile during all subsequent measurements. Use of the free 25OHD index showed similar results. No independent predictors of changes in vitamin D tertiles during follow-up were identified, which suggests that the observed variation was caused by the intra-individual variation in measured parameters. For all participants, the within-patient variability in 25OHD measurements was between 13 % and 19 %. CONCLUSIONS: In healthy postmenopausal women, HRT increases Gc levels. Owing to the high intra-individual variation in plasma 25OHD, it seems questionable to use a single estimate as a predictor of individual vitamin D status.
RCT Entities:
OBJECTIVE: Measurement of plasma 25-hydroxyvitamin D (25OHD) level is often used to evaluate a patient's vitamin D status. The purpose of this study was to investigate the variability in individual plasma 25OHD- and vitamin D-binding protein- (Gc) levels over a 5-year period in postmenopausal women with and without hormone replacement therapy (HRT). MATERIAL AND METHODS: A total of 187 women were followed-up for 5 years. At baseline, 89 women were allocated to treatment with HRT, given orally. Measurements were performed at baseline and after 1, 2 and 5 years of follow-up. RESULTS: At baseline, 25OHD levels were positively associated with sunbathing and use of vitamin D supplements, and inversely associated with smoking. HRT therapy increased plasma levels of Gc (+8 %) but did not affect 25OHD levels or the free 25OHD index (molar ratio of 25OHD- to Gc levels). Among those classified in the lowest 25OHD tertile at baseline, 40 % remained in the lowest tertile during all subsequent measurement time-points. Similarly, 32 % of those classified in the highest baseline tertile remained in the highest tertile during all subsequent measurements. Use of the free 25OHD index showed similar results. No independent predictors of changes in vitamin D tertiles during follow-up were identified, which suggests that the observed variation was caused by the intra-individual variation in measured parameters. For all participants, the within-patient variability in 25OHD measurements was between 13 % and 19 %. CONCLUSIONS: In healthy postmenopausal women, HRT increases Gc levels. Owing to the high intra-individual variation in plasma 25OHD, it seems questionable to use a single estimate as a predictor of individual vitamin D status.
Authors: Jonathan N Hofmann; Kai Yu; Ronald L Horst; Richard B Hayes; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Melissa A Kluczynski; Jean Wactawski-Wende; Mary E Platek; Carol A DeNysschen; Kathleen M Hovey; Amy E Millen Journal: J Nutr Date: 2012-07-25 Impact factor: 4.798
Authors: Cassianne Robinson-Cohen; Andrew N Hoofnagle; Joachim H Ix; Michael C Sachs; Russell P Tracy; David S Siscovick; Bryan R Kestenbaum; Ian H de Boer Journal: JAMA Date: 2013-07-10 Impact factor: 56.272
Authors: David C Gibbs; Veronika Fedirko; Caroline Um; Myron D Gross; Bharat Thyagarajan; Roberd M Bostick Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 4.897
Authors: Cassianne Robinson-Cohen; Ronit Katz; Andrew N Hoofnagle; Jane A Cauley; Curt D Furberg; John A Robbins; Zhao Chen; David S Siscovick; Ian H de Boer; Bryan Kestenbaum Journal: J Clin Endocrinol Metab Date: 2011-04-20 Impact factor: 5.958
Authors: Ian H de Boer; Bryan Kestenbaum; Abigail B Shoben; Erin D Michos; Mark J Sarnak; David S Siscovick Journal: J Am Soc Nephrol Date: 2009-05-14 Impact factor: 10.121
Authors: Unhee Lim; D Michal Freedman; Bruce W Hollis; Ronald L Horst; Mark P Purdue; Nilanjan Chatterjee; Stephanie J Weinstein; Lindsay M Morton; Arthur Schatzkin; Jarmo Virtamo; Martha S Linet; Patricia Hartge; Demetrius Albanes Journal: Int J Cancer Date: 2009-02-15 Impact factor: 7.396